Fonte: Atherosclerosis. Nome do evento: Congress of the European Atherosclerosis Society. Unidade: FM
Assunto: ENDOCRINOLOGIA/METABOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARRILHO, Alexandre José Faria et al. Hepatic CETP expression is lowered by cholestyramine or lovastatin administration to human CETP transgenic and LDL receptor knock out heterozigous mice. Atherosclerosis. Amsterdam: Elsevier. . Acesso em: 14 out. 2024. , 1999APA
Carrilho, A. J. F., Harada, L. M., Passarelli, M., Medina, W. L., Oliveira, H. C. F., Nakandakare, E. R., et al. (1999). Hepatic CETP expression is lowered by cholestyramine or lovastatin administration to human CETP transgenic and LDL receptor knock out heterozigous mice. Atherosclerosis. Amsterdam: Elsevier.NLM
Carrilho AJF, Harada LM, Passarelli M, Medina WL, Oliveira HCF, Nakandakare ER, Agellon LB, Quintão EC da R. Hepatic CETP expression is lowered by cholestyramine or lovastatin administration to human CETP transgenic and LDL receptor knock out heterozigous mice. Atherosclerosis. 1999 ; 144 166.[citado 2024 out. 14 ]Vancouver
Carrilho AJF, Harada LM, Passarelli M, Medina WL, Oliveira HCF, Nakandakare ER, Agellon LB, Quintão EC da R. Hepatic CETP expression is lowered by cholestyramine or lovastatin administration to human CETP transgenic and LDL receptor knock out heterozigous mice. Atherosclerosis. 1999 ; 144 166.[citado 2024 out. 14 ]